Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with a hip or knee prosthetic joint infection due to S. aureus as an adjunct to surgical treatment

Next Previous
Trial Profile

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with a hip or knee prosthetic joint infection due to S. aureus as an adjunct to surgical treatment

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP SA01 (Primary) ; AP SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 09 May 2019 According to an Armata Pharmaceuticals media release, IND application for Staphylococcus aureus bacteremia is planned for 2019.
  • 09 May 2019 C3J Therapeutics and AmpliPhi Biosciences have merged together and formed Armata Pharmaceuticals, Inc.
  • 27 Sep 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top